Erectile dysfunction (ED) is one of the commonest pathologies affecting the middle-aged men, with a negative impact on the quality of life. Around 30% of male patients above 40 years suffer from this condition, with increasing rates in older ages (1). Besides the great developments in this field, regarding both pathophysiology and treatment, some patients still lack the satisfactory response to the available treatments. These include: oral drugs [5-phosphodiesterase inhibitors (PDE5-I) both in daily regimen (tadalafil 5 mg) and on demand regimen (all the products commercially available)]; intra-urethral and intra-cavernous alprostadil (on demand regimen); vacuum devices; and penile prosthetic implant. All the approved treatments are unable to alter the underlying pathologic process, and achieve a “cure” for this problem (2). On the other hand, non-responders lack an effective therapeutic weapon, remaining the penile prosthesis as the unique, but irreversible, solution.
In the last years, some innovative options appeared in order to face this problem, and some studies have shown good results with the use of low-intensity extracorporeal shockwave therapy (Li-ESWT) in the corpora cavernosa.
Acknowledging that the reduction in the blood flow in the cavernosal arteries and the endothelial dysfunction are the hallmarks of ED, Vardi and colleagues (3) were the first to study this subject in 2010. Expertise obtained in other medical fields (mainly Cardiology, Plastic surgery and Orthopaedics, that used the same technology to treat myocardial infarction, skin wounds and bone fractures, respectively), this group hypothesized that the neovascularization could improve the cavernosal blood flow. Since then, many studies and clinical trials have been published in this topic. Recently, the European Urological Association has listed Li-ESWT as a possible treatment for ED. Nevertheless, however there isn’t a consensus about the efficacy of this tool in the ED setting, the type of schedule nor in which patients the benefit could be maximized (4).
The present study aims to determine the impact and efficacy of Li-EWST in male patients with ED.
The present study is a single-center, pilot clinical study to evaluate the efficacy and safety of Li-EWST.
A total of 18 adult men with ED, who met the inclusion criteria, were enrolled in this study. The Li-EWST protocol was applied between January and December 2016 by the same urologist.
Inclusion criteria were: age >18 years, history of ED with duration of at least 12 months, without good results with the use of PDE5-I (either non-responders, unsatisfied with the regimen, or with formal contra-indication).
Exclusion criteria included: neurologic etiology (with overt neurologic disease diagnosis such as Parkinson’s disease or multiple sclerosis), psychogenic etiology, endocrinologic disorder (hypogonadism, hypothyroidism), iatrogenic ED (post-operative, mainly after radical prostatectomy, or other extensive pelvic surgery), psychiatric disorder, penile anatomical abnormalities, clinically significant chronic hematological disease, anti-androgens or radiotherapy treatment of the pelvic region.
Men were provided with verbal information with regard to the study protocol and gave their written informed consent. The Institutional Review Board at the Centro Hospitalar Vila Nova de Gaia/Espinho approved this study.
Participants underwent a standard assessment that included medical history, physical examination and blood testing. Data was also collected for comorbidities (diabetes mellitus, arterial hypertension, tobacco abuse) and past experience with any ED treatment. A self-administered symptoms questionnaire [International Index for Erectile Function short form (IIEF-5), validated for the Portuguese language (5)] was used. No other treatment for ED was allowed during treatment. In subjects previously treated for ED, a 4-week washout period was implemented.
Participants received 4 weekly treatment sessions of Li-ESWT.
Treatments were carried out using a handheld Duolith® SD1 machine (Storz, Tägerwilen, Switzerland) set at 0.15 mJ/mm2, 5 Hz, with a total of 3,000 impulses. Li-ESWT was performed in six positions on the penis (penile shaft proximally and distally at right and left corpora cavernosa, right crus and left crus) and given by a urologist.
After the treatment each participant was asked about the effects and side-effects.
The treatment was expectably painless, not requiring any anaesthetic procedure or analgesic medication. Each session lasted approximately 30 minutes, and was conducted in an outpatient basis.
The primary outcome measure was the change in IIEF-5 score from baseline to after 1 and 3 months. Changes in IIEF-5 score of at least 4 points were considered clinically relevant (8,9). Secondarily, we assessed the clinical impact of the treatment by using, at 1- and 3-months, both the Sexual Encounter Profile (SEP) diaries (Questions 2 and 3)—SEP-Q2 “Were you able to insert your penis into your partner’s vagina?” and SEP-Q3 “Did your erection last long enough for you to have successful intercourse?” and the Global Assessment Question (GAQ) by answering the yes/no question: (GAQ-Q1) “Over the past four weeks has the treatment you have been taking improved your erectile function?”.
A descriptive analysis was performed, defining the baseline population characteristics and exploring the main results in the cohort. The IIEF-5 scores at baseline and at 1- and 3-month follow-up were compared using the McNemar’s test for a matched pairs analysis. Statistical analysis was performed by the program Statistical Package for Social Sciences, version 22.0 (SPSS Inc., Chicago, IL, USA). P values <0.05 were considered statistically significant.
Of the 18 men enrolled in the study, all completed the follow-up of 3 months.
Population demographic and clinical features are shown in Table 1. The mean age of the cohort was 61.1±7.2 years old. They scored an average 11.6±4.8 (range, 5–21) points in the IIEF-5 pre-treatment. In total, 55.6% of the patients were PDE5-I non-responders.
|Age (years), mean ± SD||61.1±7.2|
|Tobacco abuse, %||38.9|
|Response to PDE5-I, %|
|Response do alprostadil IC, %|
SD, standard deviation; PDE5-I, phosphodiesterase-5 inhibitor; alprostadil IC, intracavernous alprostadil.
The Li-ESWT sessions took place 100% in outpatient basis. All patients were able to complete the scheduled treatment.
During treatment, 55% referred the appearance of “de novo” spontaneous erections.
After treatment, no difference in the average IIEF-5 score was observed (12.3±4.2 at 1 month, P=0.36 and 12.3±4.3 at 3 months, P=0.33). Only one patient (5.6%) presented significative improvement in the IIEF-5 score (>4 points). Regarding the SEP-Q2/3, also no differences were observed (Table 2). The GAQ-Q1 answers revealed 50% of positive answers at 1 month and 33% at 3 months after treatment.
|Variable||Baseline||Follow-up 1 month||Follow-up 3 month|
|Statistics||P value||Statistics||P value|
|SEP-Q2 (%)||33 (yes)||33 (yes)||n.s.||39 (yes)||n.s.|
|67 (no)||67 (no)||61 (no)|
|SEP-Q3 (%)||11 (yes)||11 (yes)||n.s.||17 (yes)||n.s.|
|89 (no)||89 (no)||83 (no)|
|GAQ-1 (%)||–||50 (yes)||–||33 (yes)||–|
|–||50 (no)||67 (no)|
IIEF-SF, International Index for Erectile Function short form; n.s., non-significant; SEP-Q2, Sexual Encounter Profile Question 2; SEP-Q3, Sexual Encounter Profile Question 3; GAQ-Q1, Global Assessment Question 1.
No patients described any discomfort or negative side effect from the treatment.
Several mechanisms have been purposed to explain the benefit from the shockwave on the penile haemodynamics. Studies have shown that shockwaves, through the creation of microbubbles in the vasculature, can cause disruption of the endothelium (13), and subsequently, a cascade of reactions contribute to an improved setting for an erection to occur: activation and recruitment of stem cells; release of vascular endothelial growth factor (VEGF) (14) with consequent neoangiogenesis; increase in nitric oxide (NO) production through activation of the endothelial NO synthase (eNOS) and through direct effect of the shockwaves (15); neuronal repair through Schwann-cell proliferation and activation (16).
Some studies in the urologic field have shown some improvement in erectile function after Li-EWST (2,3,6-9,17-20), however systematic reviews (4,21-23), with or without meta-analysis were not able to provide level I evidence regarding the benefit of this technique on the improvement of erectile function.
Our study had a baseline average IIEF-5 of 11.6±4.8 which is similar to the value presented by other groups [baseline IIEF-5 ranging between 9.5 and 14.8 (3,13,15,24-26)]. Around 40% of patients had mild to moderate ED (IIEF-5 between 12–16).
The decision to include all severity of ED was made since there is not a consensus of which group of patients would benefit the most from this treatment—the systematic review from Lu and colleagues (21) revealed that patients with mild symptoms would benefit the most, while in the randomised controlled trial (RCT) from Yee and colleagues (24) the result was more beneficial towards the group with more severe disease.
After 1 month of treatment, there was no significant changes in the baseline IIEF-5. The same was observed after 3 months. This result is very different from the majority of published reports. In fact, other groups revealed increases in IIEF-5 score from 2.5–5 (26,27). The majority of groups used the erectile function questions of the IIEF (IIEF-EF) instead of IIEF-5, but the decision on using the IIEF-5 was made on the availability of the validated questionnaire translated in Portuguese language. Those groups have shown improvement in the IIEF-EF ranging from 2 to 9 (17,19,20,28), however the absolute value of variation is not comparable taking into account the different scale of both questionnaires.
Only 3 other published articles have shown absence of significant increase on the patient-reported.
In fact, Olsen (6) and colleagues, in their RCT, described benefit when comparing the Erection Hardness Score (EHS) at baseline to 5 weeks after treatment (57% vs. 9% of patients with EHS >2), however the study failed to prove an increase in the IIEF-5 score. The authors stressed the difficulties on the interpretation of the questionnaire from the patients.
Also Yee and colleagues (24), in another RCT, did not found any significative difference between the treatment arm and the placebo (variation of 5.3 points in IIEF-EF against baseline, but with non-statistically significant difference of 1.5 points against placebo, P=0.243).
More recently, Fojecki and colleagues (29), in 2017, published an RCT where they found an average increase in the IIEF-EF score of 1.5 points, and success in treatment in 38% of patients. However, both results were similar to the sham group and thus, no benefit from the treatment was considered.
Regarding the secondary outcomes of our study, namely the response from GAQ-Q1, interestingly, a better result was found. A high percentage (50%) of patients considered that their sexual function improved, even if there were no difference in the IIEF-5 score. This may be justified by the strong influence of a placebo effect. This positive effect did not last long in time, since at 3 months, the same value decreased to 33%. This concept of loss of effect over time was also described by other groups. Olsen and colleagues (6) have shown a decrease in the ratio of patients with EHS >2 from 57% (5 weeks) to 28% (24 weeks).
The small number of patients and the study design as a pilot study do not allow to formulate any conclusion that can be generalized. Since the study group has not shown any benefit from Li-ESWT we consider that the existence of a control group (a sham treatment group as performed by many groups), in this case, would not allow to make different conclusions.
The duration of follow-up is short, compared to some groups that presented 6- (3) or 12-month follow-up (18,20). Yamaçake and colleagues (18) presented that at 12 months there was still a significant improvement, however there was some contamination in the sham group, so conclusions should be taken cautiously.
The existence of different machines (five commercially available) (13), with different sources of energy to create the low-intensity shockwaves, doesn’t allow a direct comparison of results. The same applies to the possible difference between machines that produce focussed or linear shockwaves. And, although we tried to mimic the protocol made by a group with the same equipment (6), other groups are performing different protocols with the same equipment [with different number of sessions, number of shocks/session, energy density, total amount of energy, benefit of repeating the same protocol later (29)] so the actual power of this technology remains undefined.
Another limitation is the absence of an objective measure, such as haemodynamic values obtained in a penile Doppler ultrasound. In the context of ED, the burden of the placebo effect is not considered insignificant (13), so the use of only a subjective patient-reported outcome expressed through validated questionnaires may increase that problem. Some groups have included data on cavernous artery triplex ultrasonographic parameters, and if some described a significant positive change (30,31), others failed to show any significant change (18). However, it has been also stated that the changes in microcirculation might not be detectable by the cavernosal Doppler ultrasound.
The present study failed to show a difference in the IIEF-5 in patients with ED after a treatment with Li-ESWT.
The potential of Li-ESWT remains appealing, since the possibility of having a disease-modifying treatment for ED would be unique. However, because the effect of this technique on ED remains questionable, treatment of these patients with Li-ESWT should preferably be confined to clinical trials. In the future, rigorous RCTs will better show whether this therapeutic approach is truly effective and in which subset of patients.
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/amj.2019.06.03). The authors have no conflicts of interest to declare.
Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The Institutional Review Board at the Centro Hospitalar Vila Nova de Gaia/Espinho approved this study (No. 36/2016). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. All patients provided written informed consent after explanation on the technique, expected and possible complications.
Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0/.
- Hatzimouratidis K, Amar E, Eardley I, et al. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. Eur Urol 2010;57:804-14. [Crossref] [PubMed]
- Abu-Ghanem Y, Kitrey ND, Gruenwald I, et al. Penile low-intensity shock wave therapy: a promising novel modality for erectile dysfunction. Korean J Urol 2014;55:295-9. [Crossref] [PubMed]
- Vardi Y, Appel B, Jacob G, et al. Can low-intensity extracorporeal shockwave therapy improve erectile function? A 6-month follow-up pilot study in patients with organic erectile dysfunction. Eur Urol 2010;58:243-8. [Crossref] [PubMed]
- Clavijo RI, Kohn TP, Kohn JR, et al. Effects of low-intensity extracorporeal shockwave therapy on erectile dysfunction: a systematic review and meta-analysis. J Sex Med 2017;14:27-35. [Crossref] [PubMed]
- Pechorro PS, Calvinho AM, Pereira NM, et al. Validação de uma versão portuguesa do Índice Internacional de Função Eréctil-5 (IIEF-5). Revista Internacional de Andrología 2011;9:3-9. [Crossref]
- Olsen AB, Persiani M, Boie S, et al. Can low-intensity extracorporeal shockwave therapy improve erectile dysfunction? A prospective, randomized, double-blind, placebo-controlled study. Scand J Urol 2015;49:329-33. [Crossref] [PubMed]
- Haahr M, Salling M, Pedersen DV, et al. Low-intensity extracorporeal shock wave therapy improves erectile dysfunction – a pilot study with 2-year follow-up. J Androl Gynecol 2014; In Press.
- Rosen RC, Allen KR, Ni X, et al. Minimal clinically important differences in the erectile function domain of the international index of erectile function scale. Eur Urol 2011;60:1010-6. [Crossref] [PubMed]
- Albersen M, Lue TF. Sexual dysfunction: MCID provides new perspective on erectile function research. Nat Rev Urol 2011;8:591-2. [Crossref] [PubMed]
- Nishida T, Shimokawa H, Oi K, et al. Extracorporealcardiac shock wave therapy markedly ameliorates ischemia-induced myocardial dysfunction in pigs in vivo. Circulation 2004;110:3055-61. [Crossref] [PubMed]
- Yan X, Zeng B, Chai Y, et al. Improvement of blood flow, expression of nitric oxide, and vascular endothelial growth factor by low-energy shockwave therapy in random-pattern skin flap model. Ann Plast Surg 2008;61:646-53. [Crossref] [PubMed]
- Wang CJ, Wang FS, Yang KD, et al. Shock wave therapy induces neovascularization at the tendon–bone junction. A study in rabbits. J Orthop Res 2003;21:984-9. [Crossref] [PubMed]
- Fode M, Hatzichristodoulou G, Serefoglu EC, et al. Low-intensity shockwave therapy for erectile dysfunction: is the evidence strong enough? Nat Rev Urol 2017;14:593-606. [Crossref] [PubMed]
- Qiu X, Lin G, Xin Z, Ferretti L, et al. Effects of low-energy shockwave therapy on the erectile function and tissue of a diabetic rat model. J Sex Med 2013;10:738-46. [Crossref] [PubMed]
- Gotte G, Amelio E, Russo S, et al. Short-time non-enzymatic nitric oxide synthesis from L-arginine and hydrogen peroxide induced by shock waves treatment. FEBS Lett 2002;520:153-5. [Crossref] [PubMed]
- Li H, Matheu MP, Sun F, et al. Low-energy shock wave therapy ameliorates erectile dysfunction in a pelvic neurovascular injuries rat model. J Sex Med 2016;13:22-32. [Crossref] [PubMed]
- Ruffo A, Capece M, Prezioso D, et al. Safety and efficacy of low intensity shockwave (LISW) treatment in patients with erectile dysfunction. Int Braz J Urol 2015;41:967-74. [Crossref] [PubMed]
- Yamaçake KG, Carneiro F, Cury J, et al. Low-intensity shockwave therapy for erectile dysfunction in kidney transplant recipients. A prospective, randomized, double blinded, sham-controlled study with evaluation by penile Doppler ultrasonography. Int J Impot Res 2019;31:195-203. [Crossref] [PubMed]
- Kitrey ND, Gruenwald I, Appel B, et al. Penile low intensity shock wave treatment is able to shift PDE5i nonresponders to responders: a double-blind, sham controlled study. J Urol 2016;195:1550. [Crossref] [PubMed]
- Fojecki GL, Tiessen S, Osther PJS. Effect of Linear Low-Intensity Extracorporeal Shockwave Therapy for Erectile Dysfunction—12-Month Follow-Up of a Randomized, Double-Blinded, Sham-Controlled Study. Sex Med 2018;6:1-7. [Crossref] [PubMed]
- Lu Z, Lin G, Reed-Maldonado A, et al. Low-intensity extracorporeal shock wave treatment improves erectile function: a systematic review and meta-analysis. Eur Urol 2017;71:223-33. [Crossref] [PubMed]
- Fojecki GL, Tiessen S, Osther PJS. Extracorporeal shock wave therapy (ESWT) in urology: a systematic review of outcome in Peyronie’s disease, erectile dysfunction and chronic pelvic pain. World J Urol 2017;35:1-9. [Crossref] [PubMed]
- Angulo JC, Arance I, de Las Heras MM, et al. Efficacy of low-intensity shock wave therapy for erectile dysfunction: a systematic review and meta-analysis. Actas Urol Esp 2017;41:479-90. [Crossref] [PubMed]
- Yee CH, Chan ES, Hou SSM, et al. Extracorporeal shock-wave therapy in the treatment of erectile dysfunction: a prospective, randomized, double-blinded, placebo controlled study. Int J Urol 2014;21:1041-5. [Crossref] [PubMed]
- Srini VS, Reddy RK, Shultz T, et al. Low intensity extracorporeal shockwave therapy for erectile dysfunction: a study in an Indian population. Can J Urol 2015;22:7614-22. [PubMed]
- Chung E, Cartmill R. Evaluation of clinical efficacy, safety and patient satisfaction rate after low-intensity extracorporeal shockwave therapy for the treatment of male erectile dysfunction: an Australian first open-label single-arm prospective clinical trial. BJU Int 2015;115:46-9. [Crossref] [PubMed]
- Hisasue S, China T, Horiuchi A, et al. Impact of aging and comorbidity on the efficacy of low-intensity shock wave therapy for erectile dysfunction. Int J Urol 2016;23:80-4. [Crossref] [PubMed]
- Bechara A, Casabé A, De Bonis W, et al. Twelve-month efficacy and safety of low-intensity shockwave therapy for erectile dysfunction in patients who do not respond to phosphodiesterase type 5 inhibitors. Sex Med 2016;4:e225-32. [Crossref] [PubMed]
- Fojecki GL, Tiessen S, Osther PJS. Effect of Low-Energy Linear Shockwave Therapy on Erectile Dysfunction—A Double-Blinded, Sham-Controlled, Randomized Clinical Trial. J Sex Med 2017;14:106-12. [Crossref] [PubMed]
- Vardi Y, Appel B, Kilchevsky A, et al. Does low intensity extracorporeal shock wave therapy have a physiological effect on erectile function? Short-term results of a randomized, double-blind, sham controlled study. J Urol 2012;187:1769-75. [Crossref] [PubMed]
- Kalyvianakis D, Memmos E, Mykoniatis I, et al. Low-Intensity Shockwave Therapy for Erectile Dysfunction: A Randomized Clinical Trial Comparing 2 Treatment Protocols and the Impact of Repeating Treatment. J Sex Med 2018;15:334-45. [Crossref] [PubMed]
Cite this article as: Costa P, Dias J, Gouveia R, Espiridião P, Pereira D, Rodrigues R, Ferraz L. Low intensity extracorporeal shockwave therapy on erectile dysfunction—first results from a prospective study. AME Med J 2019;4:32.